TECHNOLOGY
SUPERBRANCHE is a chemical company developing an innovative platform of SUPERSPIO® - our dendronized iron oxide nanoparticles for healthcare applications and primarily to improve the patient journey.
Our mission
Connecting technologies to transform the treatment and monitoring of solid cancers.
Photo: © National Cancer Institute on Unsplah
Our credo:
Let's play collectively!
It reflects the properties of our technology platform, which combines diagnostic properties with targeted therapy capabilities. But this credo also reflects our desire to move forward collectively with our partners, both in terms of production and future clinical applications.
Photo: © National Cancer Institute on Unsplah
Our innovative technology
SUPERSPIO® is an iron oxide nanoparticle technology platform with differentiating factors in line with the needs of addressable markets for therapy monitoring applications (cellular or exosome) and theranosticsThe goal was to achieve an object design small enough (around 20 nanometers) so that these nanoparticles could be injected into the bloodstream, but also for better internalization into cells or exosomes. Since blood irrigates the entire body, we can potentially reach any cancer cell or metastasis very early on.
These SPIOs (SuperParamagnetic Iron Oxides) iron oxide nanoparticles have an outer coating of dendrimers, for increased stability and performance.
SUPERBRANCHE combines the best of organic and inorganic approaches to generate hybrid nanoparticles for imaging such as Magnetic Resonance Imaging (MRI) but also MPI (Magnetic Particle Imaging). This latest technology allows for extremely sensitive monitoring and quantification of innovative therapeutic drugs without ionizing radiation, and can be combined with focused magnetic hyperthermia therapy.
SUPERSPIO® is currently produced in research grade and its industrialization to pharmaceutical grade (GMP or BPF) is in progress (see “PRODUCTION” tab).
SUPERBRANCHE has already demonstrated the maturity of its technology on a laboratory scale, in concrete industrial applications with its customers and partners (4 preclinical proofs of concept in partnership with various hospitals in France, Canada and the United States).
These nanoparticles exhibit distinctive properties, offering significant advantages in the fields of diagnostic and therapeutic medicine:
- their mode of administration : the majority of nanoparticles being too large, it is necessary to inject them directly into or near the tumor (which implies that the diagnosis has been made beforehand using another technology). On the contrary, SUPERSPIO® from SUPERBRANCHE can be injected intravenously thanks to a controlled and mastered size of less than 30 nm.
- their capacity for internalization in innovative therapy medicines : these nanoparticles open the possibility of monitoring MTIs (cells, EVs or hybrid LNPs) that have internalized SUPERSPIO® in order to guide, orient and optimize the treatment; they help to determine the actual dose arriving at the target site, thus providing additional security in regulatory dossiers by ensuring in vivo monitoring of the biodistribution of the MTI. SUPERSPIO® can be adapted to different cell-based or vesicle-based therapies, and to different diseases.
- their theranostic properties : in oncology, a dual use of these nanoparticles that can perform diagnosis and therapy in a single injection through non-ionizing imaging and treatment.
Our differentiating factors
Magnetic imaging
ADDED VALUE
Anatomical (MRI) and quantitative (MPI) imaging
Applications
- Refined diagnosis through the use of several complementary imaging modalities
Non-ionizing therapy
ADDED VALUE
Focused magnetic hyperthermia
Applications
- Reduction of side effects
- Theranostic approach to optimize the patient journey
Intravenous injection
ADDED VALUE
Any solid tumor is accessible
Applications
- Early detection
Synthesis
ADDED VALUE
Simplified production processes
Applications
- Facilitated industrialization
Our results
In vitro, our studies have demonstrated that SUPERSPIO®:
- adapts to a wide variety of cell types and applications,
- internalizes effectively without the use of toxic transfection agents,
- effectively labels iPSC cells, ideal for applications in regenerative medicine,
- has very high MPI signal efficiency, with an intensity close to 3 times higher per mass of iron compared to the VivoTrax reference, and an imaging resolution improved by 10%
In vivo, our proofs of concept have highlighted:
- MRI imaging monitoring of theranostic extracellular vesicles is possible up to 4 weeks after implantation in an animal model mimicking post-radiotherapy brain lesions (RIBI model: Radiotherapy-induced brain injury),
- MPI detection and quantification of iPSC-derived extracellular vesicles in an animal model mimicking myocardial infarction.
Technology partnership
As stated in our slogan, "Let's play collective," Superbranche wishes to continue developing its technological platform through various partnerships. Whether you are a producer of cell therapies, a biotech company, or a clinical investigation center, if you share this collaborative vision for the development of innovative diagnostic and therapeutic technologies, contact us.